Ensitrelvir as a potential treatment for COVID-19

References

• Ahmad FB, Cisewski JA, Anderson RN. Provisional mortality data - United States, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(17):597–600.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Thierry JM, Bull-Otterson L, et al., COVID-19 cases and hospitalizations among medicare beneficiaries with and without disabilities - United States, January 1, 2020-November 20, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(24):791–796.
   PubMed Web of Science ®Google Scholar
• Johnson AG, Amin AB, Ali AR, et al. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of delta and Omicron variant emergence - 25 U.S. jurisdictions, April 4-December 25, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(4):132–138.
   PubMed Web of Science ®Google Scholar
• Kirby AE, Welsh RM, Marsh ZA, et al. Notes from the field: early evidence of the SARS-CoV-2 B.1.1.529 (Omicron) variant in community wastewater - United States, November-December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(3):103–105.
   PubMed Web of Science ®Google Scholar
• Patnin S, Makarasen A, Vijitphan P, et al. Computational screening of phenylamino-phenoxy-quinoline derivatives against the main protease of SARS-CoV-2 using molecular docking and the ONIOM method. Molecules. 2022;27(6):1793.
   PubMed Web of Science ®Google Scholar
• McKimm-Breschkin JL, Hay AJ, Cao B, et al. COVID-19, Influenza and RSV: surveillance-informed prevention and treatment - meeting report from an isirv-WHO virtual conference. Antiviral Res. 2022;197:105227.
   PubMed Web of Science ®Google Scholar
• Uraki R, Kiso M, Iida S, et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature. 2022;23:1811–1818.
   Google Scholar
• Uraki R, Kiso M, Imai M, et al. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. Nat Microbiol. 2022;7(8):1252–1258.
   PubMed Web of Science ®Google Scholar
• McCarthy MW. Outpatient treatment options to address the SARS-CoV-2 variant Omicron. Expert Rev Anti Infect Ther. 2022;20(8):1129–1133.
   PubMed Web of Science ®Google Scholar
• Moghadasi SA, Heilmann E, Moraes SN, et al. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. bioRxiv. 2022. DOI:10.1101/2022.08.07.503099.
   PubMedGoogle Scholar
• Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198:105252.
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang L. In the age of Omicron variant: paxlovid raises new hopes of COVID-19 recovery. J Med Virol. 2021;3:221–229.
   Google Scholar
• Sathish JG, Bhatt S, DaSilva JK, et al. Comprehensive nonclinical safety assessment of nirmatrelvir supporting timely development of the SARS-COV-2 Antiviral therapeutic, Paxlovid™. Int J Toxicol. 2022;29:10915818221095489.
   Web of Science ®Google Scholar
• Tan H, Hu Y, Jadhav P, et al. Progress and challenges in targeting the SARS-CoV-2 papain-like protease. J Med Chem. 2022;65(11):7561–7580.
   PubMed Web of Science ®Google Scholar
• Sánchez Fabra D, Herrero Jordán T. Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): raising concerns. Enferm Infecc Microbiol Clin. 2022. DOI:10.1016/j.eimc.2022.04.007
   PubMedGoogle Scholar
• Salerno DM, Jennings DL, Lange NW, et al. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. Am J Transplant. 2022;22(8):2083–2088.
   PubMed Web of Science ®Google Scholar
• Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge. N Engl J Med. 2022;387(9):790–798.
   PubMed Web of Science ®Google Scholar
• McCarthy MW. Novel Strategies for the Treatment of COVID-19. Drugs R D. 2022. DOI:10.1007/s40268-022-00400-8
   Google Scholar
• Unoh Y, Uehara S, Nakahara K, et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem. 2022;65(9):6499–6512.
   PubMed Web of Science ®Google Scholar
• Bartha FA, Juhász N, Marzban S, et al. In Silico evaluation of paxlovid’s pharmacometrics for SARS-CoV-2: a multiscale approach. Viruses. 2022;14(5):1103.
   PubMed Web of Science ®Google Scholar
• Eng H, Dantonio AL, Kadar EP, et al. Disposition of nirmatrelvir, an orally bioavailable inhibitor of SARS-CoV-2 3C-like protease, across animals and humans. Drug Metab Dispos. 2022;50(5):576–590.
   PubMed Web of Science ®Google Scholar
• Shini Reubina SK, Anuba PA, Swetha B, et al. Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: a evidence-based review from six databases. Diabetes Metab Syndr. 2022;16(3):102451.
   PubMed Web of Science ®Google Scholar
• Moghadasi SA, Esler MA, Otsuka Y, et al. Gain-of-signal assays for probing inhibition of SARS-CoV-2 M. mBio. 2022;13(3):e0078422.
   PubMed Web of Science ®Google Scholar
• Ullrich S, Ekanayake KB, Otting G, et al. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorg Med Chem Lett. 2022;62:128629.
   PubMed Web of Science ®Google Scholar
• Collins FS, Stoffels P. Accelerating COVID-19 Therapeutic Interventions And Vaccines (ACTIV): an unprecedented partnership for unprecedented times. JAMA. 2020;323(24):2455–2457.
   PubMed Web of Science ®Google Scholar
• Mukae H, Yotsuyanagi H, Ohmagari N, et al. A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part. Antimicrob Agents Chemother. 2022;66(10):e0069722.
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• Selvaraj V, Finn A, Lal A, et al. Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials. EClinicalMedicine. 2022;49:101489.
   PubMedGoogle Scholar
• Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10(4):327–336.
   PubMed Web of Science ®Google Scholar
• Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022.
   Google Scholar
• Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–1057.
   PubMed Web of Science ®Google Scholar
• Soriano V, de-Mendoza C, Edagwa B, et al. Oral antivirals for the prevention and treatment of SARS-CoV-2 infection. AIDS Rev. 2022;24(1). DOI:10.24875/AIDSRev.22000001.
   Web of Science ®Google Scholar
• Lee TC, Murthy S, Del Corpo O, et al. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;31:4101–4109.
   Google Scholar
• Mahase E. Covid-19: remdesivir has “small effect” against death or progression to ventilation, WHO trial finds. Bmj. 2022;377:o1118.
   PubMedGoogle Scholar
• Turk C, Turk S, Malkan UY, et al. Three critical clinicobiological phases of the human SARS-associated coronavirus infections. Eur Rev Med Pharmacol Sci. 2020;24(16):8606–8620.
   PubMed Web of Science ®Google Scholar